← back to search

Usha Menon

Amrita Institute of Medical Sciences and Research Centre · US
Area of research
Reproductive Medicine · Genetics
Research interest
Research interests include Ovarian cancer diagnosis and treatment, BRCA gene mutations in cancer, Global Cancer Incidence and Screening, and Endometrial and Cervical Cancer Treatments.
h-index
94
citations
40,532
works
935
NIH funding
primary concept
Medicine
email

Recent publications

Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer
JAMA Network Open 2025cited by 4position: middledoi
Screening and prevention of ovarian cancer
The Medical Journal of Australia 2024cited by 95position: middledoi
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality
JAMA 2024cited by 90position: middledoi
Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study
The Lancet Oncology 2024cited by 35position: middledoi
Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
Nature Biotechnology 2024cited by 27position: middledoi
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions
The American Journal of Human Genetics 2024cited by 25position: middledoi
Alcohol intake and endogenous sex hormones in women: Meta‐analysis of cohort studies and Mendelian randomization
Cancer 2024cited by 19position: middledoi
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Journal of Clinical Investigation 2024cited by 17position: middledoi
Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Clinical Cancer Research 2024cited by 12position: middledoi
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction
Breast Cancer Research 2024cited by 11position: middledoi
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials
Contemporary Clinical Trials 2024cited by 11position: middledoi
Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction
medRxiv 2024cited by 10position: middledoi
Evolutionary dynamics in the decades preceding acute myeloid leukaemia
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 9position: middledoi
Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer
International Journal of Gynecological Cancer 2024cited by 8position: middledoi
Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk
medRxiv 2024cited by 3position: middledoi
Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
JNCI Journal of the National Cancer Institute 2023cited by 25position: middledoi
Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility
JAMA Network Open 2023cited by 11position: middledoi
A Likelihood Ratio Approach for Utilizing Case-Control Data in the Clinical Classification of Rare Sequence Variants: Application to BRCA1 and BRCA2
Human Mutation 2023cited by 6position: middledoi
Alcohol intake and endogenous sex hormones in women: meta-analysis of cohort studies and Mendelian randomization
Research Square 2023cited by 6position: middledoi
Co-Creation of Breast Cancer Risk Communication Tools and an Assessment of Risk Factor Awareness: A Qualitative Study of Patients and the Public in India
Cancers 2023cited by 6position: lastdoi
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
Journal of Medical Genetics 2023cited by 5position: middledoi
Concurrent RB1 loss and <i>BRCA</i> -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
medRxiv 2023cited by 5position: middledoi
Scientific Business Abstracts
QJM 2023cited by 0position: middledoi
Cancer disparities in the context of rurality: risk factors and screening across various U.S. rural classification codes
Cancer Causes & Control 2022cited by 42position: middledoi
Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia
Journal of Clinical Oncology 2022cited by 30position: middledoi
Profiling the immune landscape in mucinous ovarian carcinoma
Gynecologic Oncology 2022cited by 26position: middledoi
Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews
Diagnostics 2022cited by 6position: middledoi
Randomised trial of population‐based <scp><i>BRCA</i></scp> testing in Ashkenazi Jews: long‐term secondary lifestyle behavioural outcomes
BJOG An International Journal of Obstetrics & Gynaecology 2022cited by 6position: middledoi
Reproductive Factors Do Not Influence Survival with Ovarian Cancer
2022cited by 2position: middle
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
The Lancet 2021cited by 684position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Ranjit Manchanda · All India Institute of Medical Sciences Bhubaneswar21 papers (2014–2024)Ian Jacobs · Children's Hospital of Philadelphia17 papers (2013–2022)Rosa Legood · London School of Hygiene & Tropical Medicine17 papers (2014–2022)Faiza Gaba · University of Aberdeen10 papers (2018–2022)Aleksandra Gentry‐Maharaj · Respiratory Clinical Trials10 papers (2013–2024)Matthew Burnell · University College London9 papers (2013–2022)Antonis C. Antoniou · University of Cambridge9 papers (2016–2023)Paul D.P. Pharoah · University of Thessaly7 papers (2015–2023)D. Gareth Evans · Translational Research Institute6 papers (2017–2021)Chris Jacobs · Université Claude Bernard Lyon 16 papers (2014–2022)Saskia C. Sanderson · Genomics (United Kingdom)6 papers (2014–2022)Yvonne Wallis · Cambridge University Hospitals NHS Foundation Trust6 papers (2014–2022)Lucy Side · Centre For Human Genetics6 papers (2014–2022)Huw Dorkins · Hebrew University of Jerusalem5 papers (2014–2022) · 5 papers (2014–2022) · 5 papers (2014–2022)Uziel Beller · Hebrew University of Jerusalem5 papers (2014–2022)Andy Ryan · MRC Clinical Trials Unit at UCL5 papers (2016–2021)Ian Tomlinson · Science Oxford5 papers (2014–2022)Susan J. Ramus · Cancer Institute of New South Wales5 papers (2017–2023)